[JP Morgan] '15 Years in Business' Eubiologics: “Moving Beyond Cholera to Premium 슬롯사이트 볼트카지노메이저s...aiming to become a ‘Great-Global Company’”

[by Kang, In Hyo] EuBiologics, a 슬롯사이트 볼트카지노메이저 research and development (R&D) and manufacturing company celebrating its 15th anniversary this year, is preparing for a transformative year in which it aims to become a ‘great’ and ‘global’ company. The strategy involves expanding its R&D efforts beyond the public health market, where it has established a strong presence with its oral cholera 슬롯사이트 볼트카지노메이저s (Euvichol, Euvichol-Plus, Euvichol-S). The company plans to target the ‘premium 슬롯사이트 볼트카지노메이저 (high value-added 슬롯사이트 볼트카지노메이저)’ market, which includes 슬롯사이트 볼트카지노메이저s for respiratory syncytial virus (RSV), shingles, and Alzheimer’s disease. Furthermore, EuBiologics intends to expand its clinical trials region from Korea to the U.S. and other countries, marking its commitment to entering the global 슬롯사이트 볼트카지노메이저 market.

In an interview with <THE BIO, Baik Yeong-ok, CEO of EuBiologics, shared, “I began attending the JP Morgan Healthcare Conference in 2018, and I’ve been officially invited to attend three times, in 2020, 2023, and this year.” He added, “It has been immensely helpful in understanding the trends of major global pharmaceutical companies and shaping our development strategies and directions.” Currently, EuBiologics’ primary business focus remains on public market 슬롯사이트 볼트카지노메이저s, with its flagship product being its oral cholera 슬롯사이트 볼트카지노메이저s.

The company supplies oral cholera 슬롯사이트 볼트카지노메이저s to UNICEF, with sales of cholera 슬롯사이트 볼트카지노메이저s reaching KRW 65.4 billion (approximately USD 44.8 million) in 2023. Cumulative sales up until Q3 2024 were approximately KRW 57.6 billion. Additionally, the improved cholera 슬롯사이트 볼트카지노메이저, ‘Euvichol-S, received prequalification (PQ) approval from the World Health Organization (WHO) in April of last year and was first shipped in October of the same year.

“EuBiologics is the only company in the world that exclusively supplies cholera 슬롯사이트 볼트카지노메이저s and has achieved the status of a ‘good company’ by reaching KRW 100 billion in sales from our cholera 슬롯사이트 볼트카지노메이저s,” Baik stated. “We will not rest on this success and are committed to continuously developing 슬롯사이트 볼트카지노메이저 platforms and expanding our R&D pipelines to transform into a ‘great company.’”

“Last November, we received an award letter from UNICEF for the supply of oral cholera 슬롯사이트 볼트카지노메이저s worth KRW 149 billion (approximately USD 102.1 million) for next year, and the total amount requested by UNICEF for 2026 has been confirmed to be 72 million doses,” Baik further commented. “This year will be a ‘year of leap forward,’ with sales of KRW 150 billion as a given, and we expect even higher sales growth thanks to the favorable exchange rate.”

Based on the growth of cholera 슬롯사이트 볼트카지노메이저s in the public health market, EuBiologics is also actively targeting the premium 슬롯사이트 볼트카지노메이저 market. “We are developing RSV and shingles 슬롯사이트 볼트카지노메이저 candidates using the ‘EuIMT platform technology’ that we used to develop the COVID-19 슬롯사이트 볼트카지노메이저 candidate,” Baik said. “We have confirmed the excellence of our platform technology, and we have also reached out to a major global pharmaceutical company. They have expressed their interest in discussing further after seeing the results of the phase 1 clinical trial.’”

“We began phase 1 clinical trials for our RSV and shingles 슬롯사이트 볼트카지노메이저 candidates in January and March of last year, respectively, and aim to complete the administration in the first half of this year, followed by entering phase 2 clinical trials in the second half,” he further added. “For phase 2 clinical trials, we are contemplating conducting global clinical trials in Eastern Europe, Australia, and the United States, and we plan to discuss this with consulting firms and clinical trial contract organizations (CROs) at this JP Morgan Healthcare Conference.”

The EuIMT platform technology was developed using the antigen display technology (SNAP) from POP Biotech, a U.S. company in which EuBiologics has directly invested, and the immune booster (EcML) introduced from the Korea Institute of Science and Technology (KIST). This technology is designed to promote rapid antibody responses, generate high neutralizing antibodies, and provide strong cellular immune responses. EuBiologics' 'EuCorVac-19', currently in phase 3 clinical trials, is a recombinant protein-based COVID-19 슬롯사이트 볼트카지노메이저 candidate. It is a safe 슬롯사이트 볼트카지노메이저 candidate that combines an immune booster with the core antigen of the COVID-19 virus, produced through genetic recombination technology.

"EUPOP Life Sciences, a joint venture (JV) formed with POP Biotech in 2020, is focused on developing premium 슬롯사이트 볼트카지노메이저s like RSV and shingles," Baik explained. "Along with these two 슬롯사이트 볼트카지노메이저 candidates, we are also working on an Alzheimer's disease 슬롯사이트 볼트카지노메이저 and plan to submit an IND application in Korea by the end of the year."

EuBiologics was listed on the KOSDAQ market in 2017 through the technology special exception method. The company initially thrived, recording surplus for two consecutive 슬롯사이트 볼트카지노메이저s in 2018 and 2019. However, the impact of the COVID-19 pandemic in 2020 led to a three-슬롯사이트 볼트카지노메이저 streak of deficits. Despite this, EuBiologics made a successful comeback in 2023, reporting sales of approximately KRW 68.6 billion and an operating profit of around KRW 8.4 billion.

“Although I cannot disclose the exact figures, we anticipate a further increase the profit margin from 2024, driven by the smooth sales of cholera 슬롯사이트 볼트카지노메이저s,” Baik remarked. “Leveraging our company’s immune enhancement technology, we plan to broaden the scope of our 슬롯사이트 볼트카지노메이저 development by creating a new platform. This will enable us to not only develop our existing infectious disease prevention 슬롯사이트 볼트카지노메이저s but also cancer 슬롯사이트 볼트카지노메이저s, metabolic disease 슬롯사이트 볼트카지노메이저s, and messenger ribonucleic acid (mRNA) 슬롯사이트 볼트카지노메이저s.”

“EuBiologics produces raw drug substances (DS), such as 슬롯사이트 볼트카지노메이저 antigen concentrates, as well as adjuvants (immune boosters), and we have plans to build a facility for the production of finished drug products (DP),” Baik further emphasized. “Currently, we can produce phase 1 and 2 clinical samples in-house, but once we enter the commercial production stage, we intend to establish our own production facilities. Our company aims to evolve into one that can independently produce the entire 슬롯사이트 볼트카지노메이저 development process, from concentrates to adjuvants to finished products.”